Close Menu
Home › Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Dec 04, 2019
|
staff reporter

NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.

Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling. 

Financial and other terms of the partnership were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

What's Popular?

In Sequencing

  1. Diagnostics Developers Leap Into Action on Novel Coronavirus Tests

    Premium

  2. Adaptive Biotechnologies Prices Public Offering of Stock

  3. Quest Diagnostics Acquires Blueprint Genetics

  4. Immunis.AI Targets Late 2020 Prostate Cancer Risk Core Assay Launch

    Premium

  5. Adaptive Biotechnologies Announces Preliminary FY19 Revenue Increase, $257M Stock Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.